Market Overview - The medical beauty sector experienced a decline of 1.41% on January 27, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Individual Stock Performance - Aimei Ke (300896) closed at 140.31, down 1.20% with a trading volume of 31,300 shares and a transaction value of 439 million [1] - Jinbo Biological (920982) closed at 228.34, down 1.31% with a trading volume of 5,531 shares and a transaction value of 127 million [1] - Huaxi Biological (688363) closed at 46.43, down 1.59% with a trading volume of 49,700 shares and a transaction value of 229 million [1] - *ST Meigu (000615) closed at 3.19, down 2.15% with a trading volume of 108,900 shares and a transaction value of 34.8 million [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 41.32 million from main funds and a net outflow of 3.13 million from speculative funds, while retail investors had a net inflow of 44.45 million [1] - For *ST Meigu, the main funds had a net outflow of 9.71 million, accounting for -27.91% of the total, while retail investors had a net inflow of 7.40 million, representing 21.26% [2] - Huaxi Biological experienced a net outflow of 14.32 million from main funds, with a net inflow of 4.64 million from retail investors [2] - Aimei Ke had a net outflow of 17.28 million from main funds, with a net inflow of 32.41 million from retail investors [2] - Jinbo Biological saw a net outflow of 19.33 million from main funds, with a net outflow of 188,440 from retail investors [2]

Group 1 - The medical beauty sector experienced a slight decline of 0.03% on January 26, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the medical beauty sector showed mixed performance, with Huaxi Biological up 1.03% and *ST Meigu down 1.81% [1] Group 2 - The medical beauty sector saw a net outflow of 14.71 million yuan from main funds, while retail investors contributed a net inflow of 8.53 million yuan [1] - Detailed fund flow data indicates that Huaxi Biological had a main fund net inflow of 5.91 million yuan, while *ST Meigu experienced a significant main fund net outflow of 7.46 million yuan [2] - Retail investors showed a positive net inflow in several stocks, with Love Beauty seeing a retail net inflow of 26.41 million yuan despite a main fund outflow [2]

Group 1: Quantum Technology - The report highlights significant advancements in quantum error correction technology, with Zhejiang University and Tsinghua University demonstrating low-overhead quantum error correction codes, effectively reducing logical error rates below physical error rates [4][5] - Horizon Quantum Computing has formed a strategic partnership with Alice&Bob to accelerate the development of fault-tolerant quantum computing, integrating their software and hardware capabilities [5] - GuoDun Quantum plans to sign a technology licensing contract with the University of Science and Technology of China, involving quantum random number generators and superconducting quantum computing control systems [6][7] Group 2: Biomanufacturing - The Chinese Academy of Sciences has achieved a breakthrough in synthesizing L-arginine using methanol as the sole carbon source, marking a shift towards non-grain-based production methods [8][9] - The Shenzhen Advanced Institute has developed the MARS intelligent system, which integrates multiple AI agents and robots to significantly shorten the new material development cycle from four months to four hours [9][10] - Jinbo Biological has registered a 2 billion yuan private placement to enhance its humanized collagen protein FAST database project, aiming to improve research and development efficiency [11] Group 3: Hydrogen Energy and Nuclear Fusion - The Baowu Clean Energy green hydrogen industrial park project, with a total investment of 11.09 billion yuan, has been launched in Guangdong, establishing a new model for offshore wind power direct hydrogen production [12][13] - A Chinese consortium has signed a significant contract for the ITER edge local model power supply system, marking a major step in China's contribution to global fusion energy projects [15] - Zhejiang Fu Nuclear Power will participate in the development of core components for the China Fusion Engineering Demonstration Reactor (CFEDR), focusing on ultra-high heat load components [16][17] Group 4: Brain-Computer Interfaces - Neuralink has successfully implemented OTA wireless upgrades for its invasive brain-computer interface, allowing for performance optimization without the need for additional surgeries [18][19] - This advancement addresses the traditional limitations of invasive devices, reducing clinical maintenance risks and costs while enhancing the adaptability of the technology [20] Group 5: Embodied Intelligence - World Labs, founded by Fei-Fei Li, has partnered with Guanglun Intelligent to create an evaluation system for embodied intelligence, addressing high verification costs and discrepancies between simulation and reality [21][22] - The Marble model developed by World Labs generates high-fidelity 3D environments from various inputs, solving traditional model issues but lacking physical interaction capabilities [22][23] Group 6: Future Industry Catalysts - The report outlines key catalytic events for 2026 across six future industries, including significant conferences and technological milestones that investors should monitor [28][29]

Core Insights - The report highlights a decrease in the market value of public funds heavily invested in the Beijing Stock Exchange (BSE), which reached 9.05 billion yuan as of Q4 2025, a decline of 12.19% quarter-on-quarter [2] - The report indicates that the decline is primarily due to profit-taking by investors in thematic funds, with a total redemption of 1.48 billion units, accounting for 52% of the total units before redemption [2][17] - The average net value growth rate of thematic funds in 2025 was 56.7%, significantly outperforming the BSE 50 index's growth of 38.8% [17] Public Fund Investment Trends - As of Q4 2025, the market value of public funds invested in the BSE accounted for 0.27% of the total A-share market, a decrease of 0.04 percentage points [3][4] - The report notes that passive investment trends are ongoing, with index funds experiencing net subscriptions for three consecutive quarters, totaling 12.838 billion yuan as of Q4 2025, an increase of 7.55 billion yuan [2][13] - The report anticipates continued institutional investment in the BSE, with eight thematic funds pending market entry, including six index funds and two actively managed funds [2] Active Equity Fund Strategies - Active equity public funds are focusing on low-valuation growth stocks, with the valuation center of the top 10 stocks held by these funds dropping to 39 times earnings, below the valuation center of the BSE A-shares [2][20] - Key stocks of interest include Litong Technology (solid-state battery), Tongli Co. (lowest valuation on the BSE), and Lin Tai New Materials (low-valuation high-performance) [2][22] - The report also notes an increased focus on cyclical manufacturing sectors, such as basic chemicals and machinery, while reducing exposure to consumer sectors like beauty care and agriculture [2] Thematic Fund Performance - The report emphasizes that thematic funds have shown significant excess returns, with the average net value growth rate of thematic funds in 2025 being 56.7%, compared to the BSE 50's growth of 38.8% [17] - Specific funds that performed well include the "Hua Xia BSE Innovation Small and Medium Enterprises Selected Two-Year Open Fund," which had the lowest redemption ratio [2][15] - The report identifies a trend of active equity public funds increasing their holdings in stocks like Litong Technology, Tongli Co., and Lin Tai New Materials, indicating a strategic shift towards promising sectors [22]

Group 1 - The core point of the article is that Jinbo Biopharmaceutical (920982) has received approval from the China Securities Regulatory Commission (CSRC) for a specific stock issuance, which is valid for 12 months from the date of approval [1] - As of January 23, 2026, Jinbo Biopharmaceutical's stock closed at 229.45 yuan, up 1.08% from the previous trading day, with a total market capitalization of 26.402 billion yuan [1] - The stock opened at 230.0 yuan, reached a high of 233.98 yuan, and a low of 229.0 yuan, with a trading volume of 1.7 billion yuan and a turnover rate of 1.34% [1] Group 2 - The company will handle related matters based on the approval and authorization from the shareholders' meeting, ensuring timely information disclosure [1]

Group 1 - Ainanju (920770) announced that several shareholders plan to reduce their holdings, with a maximum reduction of 147.17 thousand shares (1.1309%) by Jiaxing Xinmeng Investment Co., Ltd. and 67.92 thousand shares (0.5219%) by Zhang Lianghua [2] - Huaguangyuanhai (920351) reported that its controlling shareholders intend to reduce their stakes, with a maximum reduction of 43.6875 thousand shares (0.5%) by Changsha Yuan San Enterprise Management Consulting Partnership and similar reductions by other related parties [3] - Xinganjiang (920367) disclosed that major shareholders have completed their share reduction plans, with Zhang Ming reducing 55.9803 thousand shares (0.79%) for a total of 12.23 million yuan [4] Group 2 - Jinbo Biological (920982) received approval from the China Securities Regulatory Commission for a stock issuance to specific investors, valid for 12 months [5] - Danna (920009) signed a significant construction contract worth approximately 126 million yuan with China Construction Sixth Engineering Bureau, scheduled to start on January 26, 2026 [6] - Parallel Technology (920493) plans to purchase GPU computing servers and other assets, with total contracts not exceeding 185.2 million yuan [7] Group 3 - Fujida (920640) announced that two IEC international standards it led have been approved for publication, filling a gap in international specifications for RF coaxial cable components [8][9] - Honghai Technology (920108) plans to invest approximately 95.4 million yuan in constructing a new factory in Thailand as part of its strategic development [10] - Yintu Network (920508) reported the purchase of financial products totaling 24 million yuan to enhance the efficiency of its idle funds [11] - Jiangtian Technology (920121) announced a cash management initiative using 50 million yuan of idle funds [12]

证券简称：锦波生物 证券代码：920982.BJ 山西锦波生物医药股份有限公司 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. 山西省转型综合改革示范区太原唐槐园区锦波街 18 号 2025 年度向特定对象发行股票 募集说明书 （修订稿） 保荐机构 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 签署日期：二零二五年十二月 声明 本公司及控股股东、实际控制人、全体董事、董事会审计委员会成员、高级管理人员承诺募集 说明书不存在虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律 责任。 本公司负责人和主管会计工作的负责人、会计机构负责人保证募集说明书中财务会计资料真实、 准确、完整。 对本公司发行证券申请予以注册，不表明中国证监会和北京证券交易所对该证券的投资价值或 者投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，本公司经营与收益的变化，由本公司自行负责，由此变化引致的投资 风险，由投资者自行负责。 1-1-1 | 声明 | 1 | | --- | --- | | 目录 | 2 | | 第一节 ...

证券代码：920982 证券简称：锦波生物 公告编号：2026-001 山西锦波生物医药股份有限公司 敬请广大投资者关注，并注意投资风险。 特此公告。 山西锦波生物医药股份有限公司 董事会 的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 山西锦波生物医药股份有限公司（以下简称"公司、发行人"）申请向特定 对象发行股票并在北京证券交易所上市（以下简称"本次股票发行"），于 2026 年 1 月 22 日收到中国证券监督管理委员会《关于同意山西锦波生物医药股份有 限公司向特定对象发行股票注册的批复》（证监许可〔2026〕114 号），同意公 司向特定对象发行股票的注册申请，该批复自同意注册之日起 12 个月内有效。 公司董事会将按照上述批复文件要求及公司股东会的授权在规定期限内办 理本次向特定对象发行股票相关事宜，并及时履行信息披露义务。 关于公司向特定对象发行股票获得中国证监会注册批复 2026 年 1 月 22 日 ...

4-1-1 | | 页 次 | | --- | --- | | 、审计报告 | 1-7 | | 、财务报表 | 8-19 | | (一) 合并资产负债表 | 8-9 | | (二) 合并利润表 | 10 | | (三) 合并现金流量表 | 11 | | (四) 合并所有者权益变动表 | 12-13 | | (五) 母公司资产负债表 | 14-15 | | (六) 母公司利润表 | 16 | | (七) 母公司现金流量表 | 17 | | (八) 母公司所有者权益变动表 | 18-19 | 4-1-2 审计报告 中汇会审[2024]2226号 山西锦波生物医药股份有限公司全体股东: 一、审计意见 我们审计了山西锦波生物医药股份有限公司(以下简称锦波生物)财务报表, 包括2023年12月31日的合并及母公司资产负债表,2023年度的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及财务报表附 注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制, 公允反映了锦波生物2023年12月31日的合并及母公司财务状况以及2023年度的合 并及母公司经营成果和现金流量。 二、形 ...

上海市锦天城律师事务所 关于山西锦波生物医药股份有限公司 2025 年度向特定对象发行股票的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 | 声明事项 1 | | | --- | --- | | 释 义 3 | | | 正 文 5 | | | 一、 | 本次发行的批准和授权 5 | | 二、 | 发行人本次发行的主体资格 6 | | 三、 | 发行人本次发行的实质条件 7 | | 四、 | 发行人的设立 9 | | 五、 | 发行人的独立性 10 | | 六、 | 发行人的发起人、股东及实际控制人 11 | | 七、 | 发行人的股本及其演变 12 | | 八、 | 发行人的业务 13 | | 九、 | 关联交易及同业竞争 14 | | 十、 | 发行人的主要财产 15 | | 十一、 | 发行人的重大债权债务 16 | | 十二、 | 发行人的重大资产变化及收购兼并 17 | | 十三、 | 发行人章程的制定与修改 17 | | 十四、 | 发行人股东（大）会、董事会、监事会议事规则 ...